TEVA TEVA PHARMACEUTICAL-SP ADR
2026Q1 · CUSIP 881624209 · Sector: Healthcare & Biotech
Lit · Institutions accelerating in
Holders
648
Δ holders QoQ
+20
Breadth percentile
Top 16%
Whale holders
241
Δ whales
+8
Inst. holding value
$20.0B
New positions
94
Closed positions
74
Price momentum (1Q)
-1.1%
Put / Call
17/22
Breadth history (34 quarters)
Past Lit Events & Aftermath 10 lit events
| Period | Percentile | Next-1Q return | Next-2Q return |
|---|---|---|---|
| 2026Q1 | Top 16% | — | — |
| 2025Q4 | Top 5% | -1.1% | — |
| 2024Q4 | Top 11% | +2.7% | +6.0% |
| 2024Q2 | Top 3% | -8.3% | -6.0% |
| 2024Q1 | Top 8% | +12.3% | +0.9% |
| 2023Q1 | Top 10% | +17.0% | +10.2% |
| 2022Q2 | Top 8% | -15.3% | -6.5% |
| 2020Q1 | Top 4% | -1.5% | -19.4% |
| 2018Q3 | Top 17% | -22.5% | -48.1% |
| 2018Q2 | Top 6% | -6.0% | -25.3% |
Options Sentiment
Put holders
17
QoQ: -13
Call holders
22
QoQ: -13
See methodology →
Fundamentals
PE (TTM)
23.7
EPS (TTM)
$1.34
EPS YoY
—
Revenue (TTM)
$17.3B
Revenue YoY
+4.4%
Quarterly Revenue & EPS (4Y)
Quarterly figures; EPS split-adjusted, early quarters hidden when not calibrable
P/E (TTM) over time
P/E = close 47 days after quarter-end (filing date) ÷ TTM EPS then; loss quarters hidden
As of 2026-03-31 · SEC filings (XBRL)